Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma 60Gliosarcoma 19Glioblastoma 19Osteosarcoma 15Lymphoma 14Central Nervous System Neoplasms 13Dendritic Cell Sarcoma, Interdigitating 11Rhabdomyosarcoma 10Oligodendroglioma 10Neuroblastoma 10Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Brain Neoplasms 10Bone Neoplasms 10Astrocytoma 10Recurrence 9Breast Neoplasms 9Sarcoma, Ewing 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Liposarcoma 8Glioma 8Burkitt Lymphoma 8Wilms Tumor 7Neoplasm Metastasis 7Melanoma 7Hodgkin Disease 7Gastrointestinal Stromal Tumors 7Ovarian Neoplasms 6Medulloblastoma 6

Interventions

pevonedistat 1Vincristine 1Rituximab 1Prednisone 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Acromesomelic dysplasia, Maroteaux type × Sarcoma × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡